Catalyst Pharmaceuticals (CPRX) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.36% |
| Dec 31, 2025 | 7.98% |
| Sep 30, 2025 | 78.38% |
| Jun 30, 2025 | 40.24% |
| Mar 31, 2025 | 38.82% |
| Dec 31, 2024 | 11.06% |
| Sep 30, 2024 | 25.31% |
| Jun 30, 2024 | 72.01% |
| Mar 31, 2024 | 132.88% |
| Dec 31, 2023 | 22.90% |
| Sep 30, 2023 | -141.05% |
| Jun 30, 2023 | 38.76% |
| Mar 31, 2023 | -31.70% |
| Dec 31, 2022 | -3.34% |
| Sep 30, 2022 | 106.98% |
| Jun 30, 2022 | 56.02% |
| Mar 31, 2022 | 30.40% |
| Dec 31, 2021 | 45.11% |
| Sep 30, 2021 | 82.26% |
| Jun 30, 2021 | 33.68% |
| Mar 31, 2021 | 13.50% |
| Dec 31, 2020 | 37.46% |
| Sep 30, 2020 | 19.72% |
| Jun 30, 2020 | 39.29% |
| Mar 31, 2020 | -17.60% |
| Dec 31, 2019 | 86.48% |
| Sep 30, 2019 | 51.93% |
| Jun 30, 2019 | -20.59% |
| Mar 31, 2019 | 33.28% |
| Dec 31, 2018 | 20.62% |
| Sep 30, 2018 | -42.98% |
| Jun 30, 2018 | -117.21% |
| Mar 31, 2018 | -118.33% |
| Dec 31, 2017 | 46.50% |
| Sep 30, 2017 | -17.93% |
| Jun 30, 2017 | -22.81% |
| Mar 31, 2017 | -24.53% |
| Dec 31, 2016 | -24.29% |
| Sep 30, 2016 | 2.97% |
| Jun 30, 2016 | -19.13% |
| Mar 31, 2016 | -44.49% |
| Dec 31, 2015 | -42.47% |
| Sep 30, 2015 | -40.48% |